Novartis ($NVS) launched a topical gel in India designed to treat pain associated with osteoarthritis, rheumatism and injury. The gel, called Voveran TPM, uses Novartis' Australian partner Phosphagenics' targeted penetration matrix (TPM) delivery system. The technology uses vitamin E phosphates to, according to Phosphagenics, "enhance dermal, transdermal and oral absorption of compounds." The new formulation is a version of Novartis' Voveran (without TPM), which is currently on the market in India as a 1% diclofenac prescription. More